TGTX vs DAR Comparison

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Darling Ingredients Inc develops and produces sustainable natural ingredients from edible and inedible bio-nutrients for the pharmaceutical, food, pet food, animal feed, industrial, fuel, bioenergy, and fertilizer industries. The Company collects and processes animal by-products and recycled oils into ingredients. It operates through three reportable segments: Feed Ingredients, which generates maximum revenue and includes the collection and processing of animal by-products, used cooking oil, bakery residuals, pet food ingredients, hides, and fertilizers; Food Ingredients, which includes collagen, natural casings, and food-grade fats; and Fuel Ingredients, which includes renewable fuels, biogas, and energy products. The Company derives the majority of its revenue from North America.